Keloids are fibrotic scars that extend beyond the boundaries of the original wound, often causing physical disfigurement and ...

Late-onset Alzheimer's disease is a debilitating, progressive neurodegenerative disease that affects about 7 million ...

Dylan Lewis: We're talking three stocks down bad. Motley Fool Money starts down. I'm Dylan Lewis, I'm joined over the airwaves by Motley Fool analyst David Meier. David, thanks for joining me today.

Aldevron, a global leader in the production of DNA, RNA and protein, has launched its latest innovation, Alchemytm cell-free DNA technology. This revolutionary technology represents a significant ...

Aldevron, a global leader in the production of DNA, RNA and protein, has launched its latest innovation, Alchemy™ cell-free ...

The expression of genes has to be carefully regulated in cells; active genes give cells their identity and ability to function... | Cell And Molecular Biology ...

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

Stay up-to-date on the top and bottom performers in the S&P 500 with this article, also highlighting key funds mirroring the ...

As the year unfolds the biotech industry will look closely at these ten first-in-class drugs on track to reach FDA approval ...

Scientists at the University of California, Irvine, have discovered that nuclear speckles, a membraneless organelle within ...

In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against the other S&P 500 stocks. Jim Cramer, host of Mad Money, recently discussed the current state of ...

Yang Zhang, Ph.D., and Jinjun Shi, Ph.D., both of the Center for Nanomedicine and Department of Anesthesiology, Perioperative ...